New PET scan trick may spot fake tumor growth in immunotherapy patients

NCT ID NCT03584334

Completed Diagnosis Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special PET scan (18FDG dual-point) can tell the difference between real tumor growth and harmless inflammation caused by immunotherapy. Researchers studied 100 people with advanced lung cancer or melanoma who were being treated with drugs like nivolumab or pembrolizumab. The goal was to find a better way to evaluate treatment response without confusing inflammation for cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18FDG PET scan (diagnostic imaging)
What this could lead to: If successful, this could help doctors quickly tell whether a tumor is truly growing or just inflamed from treatment, avoiding unnecessary changes in therapy.
What could go wrong: This is an observational study, not a treatment trial. The results may not apply to all patients or cancer types, and the scan technique is not yet standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL BRONCHOPULMONARY CARCINOMA OR MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL BRONCHOPULMONARY CARCINOMA OR MELANOMA

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.